Search results
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Summit Therapeutics SMMT reported fourth-quarter 2025 loss per share of 29 cents, wider than the Zacks Consensus Estimate of 22 cents. In the year-ago period, the company had incurred a loss of 8


